Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, Fox S, Ailts I, Dueck AC, Geyer HL, Mesa RA, Dunn WG, Nadezhdin E, Curto-Garcia N, Green A, Wilkins B, Coppell J, Laurie J, Garg M, Ewing J, Knapper S, Crowe J, Chen F, Koutsavlis I, Godfrey A, Arami S, Drummond M, Byrne J, Clark F, Mead-Harvey C, Baxter EJ, McMullin MF, Mead AJ. Harrison CN, et al. Among authors: green a. J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1. J Clin Oncol. 2023. PMID: 37126762 Free PMC article. Clinical Trial.
Equivalence of BCSH and WHO diagnostic criteria for ET.
Harrison CN, McMullin MF, Green AR, Mead AJ. Harrison CN, et al. Among authors: green ar. Leukemia. 2017 Jul;31(7):1660. doi: 10.1038/leu.2017.119. Epub 2017 May 5. Leukemia. 2017. PMID: 28474678
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Harrington P, Dillon R, Radia D, Rousselot P, McLornan DP, Ong M, Green A, Verde A, Hussain F, Raj K, Kordasti S, Harrison C, De Lavallade H. Harrington P, et al. Among authors: green a. Haematologica. 2023 Jun 1;108(6):1555-1566. doi: 10.3324/haematol.2022.282005. Haematologica. 2023. PMID: 36700403 Free PMC article.
Increased CXCL10 (IP-10) associates with advanced myeloproliferative neoplasms and its loss dampens erythrocytosis in mouse models.
Belmonte M, Cabrera-Cosme L, Øbro NF, Li J, Grinfeld J, Milek J, Bennett E, Irvine M, Shepherd MS, Cull AH, Boyd G, Riedel LM, Che JLC, Oedekoven CA, Baxter EJ, Green AR, Barlow JL, Kent DG. Belmonte M, et al. Among authors: green ar. Exp Hematol. 2024 May 17:104246. doi: 10.1016/j.exphem.2024.104246. Online ahead of print. Exp Hematol. 2024. PMID: 38763471 Free article.
John Philip Phair.
Green A. Green A. Lancet. 2024 May 18;403(10440):1980. doi: 10.1016/S0140-6736(24)00979-6. Lancet. 2024. PMID: 38763148 No abstract available.
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators. Cree BAC, et al. Among authors: green aj. Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.
Prevalence and Survival of Prolonged Venovenous Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: An Analysis of the Extracorporeal Life Support Organization Registry.
Chandel A, Fabyan KD, Mendelsohn S, Puri N, Damuth E, Rackley CR, Conrad SA, King CS, Green A. Chandel A, et al. Among authors: green a. Crit Care Med. 2024 Jun 1;52(6):869-877. doi: 10.1097/CCM.0000000000006200. Epub 2024 Feb 8. Crit Care Med. 2024. PMID: 38752812 Free PMC article.
6,704 results